At 38, my AMH was 1.1 and my baseline antral follicle count was six. My doctor suggested mild stimulation instead of a high-dose protocol, because pushing my ovaries harder would not necessarily give me more eggs. The first mild-stimulation retrieval produced five eggs, two blastocysts, and one euploid embryo after PGS. That was the moment I stopped reading brochures and started doing arithmetic: where IVF in Thailand and surrogacy in Malaysia really differ, and how many more times my body could afford to start over.
Five eggs was not failure; I ran the success-rate math first
Five eggs, two blastocysts, one chromosomally normal embryo is not a great cycle, but at 38 it is not unusual either. The clinic’s own age-stratified data said that for women aged 38 to 40, each egg retrieval has roughly a 25% to 35% chance of ending with one transferable euploid embryo. Translate that into real life: if I kept doing mild stimulation, I would need about three to four more cycles on average to bank one more usable embryo. Each cycle took around 14 days from start to retrieval, but once I added waiting for my period, waiting for PGS, and waiting for the next calendar window, one round was really about 45 days. So the real cost was close to six months and three additional retrievals for one more chance.
My practical rule became this: if your AMH is below 1.2 and you have fewer than seven baseline follicles, do not rush to compare countries first. Ask the clinic one sharper question: for my reserve, how many mild-stimulation cycles does it usually take to produce one euploid embryo? That number is more useful than any polished success-rate banner, because it tells you whether you are shopping for a destination or shopping for time you no longer have.
On Thailand IVF quotes, I obsessed over one lab line
I collected three Thailand IVF quotes, with a base cycle ranging from about RMB 90,000 to RMB 130,000. The difference was not mainly the stimulation drugs. It was the embryology language buried in the notes. Some centers wrote blastocyst culture to day five; others wrote day five to six, depending on embryo development. That sounds like a detail until you realize the spread: stronger labs can report blastulation rates above 50%, while average ones sit closer to 35%. For someone with only two blastocysts, that gap is not abstract. Fifteen percentage points can be the difference between having something to transfer and having nothing.
So I stopped asking for headline pregnancy rates and asked for one-year, age-matched data: women aged 38 to 40, blastocyst formation rate and euploidy rate, separated by age band rather than blended into a clinic-wide average. My advice for anyone reading a quote is simple: whenever you see lab wording like subject to actual development or determined case by case, ask for the statistical definition behind it. Ask how many cases that rate covers, what age group is included, and whether biochemical pregnancies are being counted as clinical ones. If a coordinator cannot produce a number, treat that line as if it does not exist. In low-reserve IVF, vague embryology terms are often where your budget quietly disappears.
What changed my mind about Malaysia was the surrogate screening file
My shift toward Malaysia surrogacy was not romantic; it was arithmetic plus exhaustion. I did not want to spend another six months betting on my own retrieval schedule when the bottleneck was no longer only egg number. The structure I looked at was straightforward: create embryos first, then match with a surrogate. The first screening report I reviewed ran to 11 pages, and I focused on three items: previous birth history, infection and genetic screening, and whether the psychological evaluation was issued by an independent body rather than the agency itself.
Birth history mattered most to me. I looked for uncomplicated vaginal deliveries, no preterm births, and newborn weight records that made sense. I also wanted to see C-section history clearly disclosed, because previous uterine surgery can change the risk conversation. On screening, the agency said only about 30% of surrogate applicants passed, meaning seven out of ten were rejected. Far from alarming me, that number reassured me. A serious program should reject most applicants. If everyone passes, it is not a screening process; it is marketing. On outcomes, the age-matched figure I was given was that a single transfer of a euploid embryo created from eggs of a 38-to-40-year-old woman had an estimated live-birth range of about 45% to 55%, somewhat higher than attempting pregnancy in my own uterus because the surrogate’s uterine environment is typically younger and more receptive. Your first move, if you ever review such a file, is to flip straight to obstetric history. Written records beat verbal promises every time.
I compared Thailand IVF and Malaysia surrogacy using only three columns
I made one spreadsheet and forced myself to compare only three columns: time to one transferable embryo, live-birth rate per transfer, and marginal cost of starting again after failure. Thailand IVF looked like this: three to four mild-stimulation cycles, roughly six months to bank another euploid embryo, and live-birth probability around 40% for my age, depending heavily on lab quality. Malaysia surrogacy looked like this: about two retrieval cycles to create embryos, roughly four months to reach transfer once matching and legal steps were moving, and live-birth odds around 50%, assuming a screened surrogate and a normal embryo. The failure scenario mattered just as much. In my own body, a failed transfer meant grief plus another cycle of ovarian stimulation. In a surrogacy pathway, a failed transfer still hurt, but the next attempt did not automatically require me to produce more eggs immediately.
That framing kept me honest. The question was not which country sounded more advanced. It was where the next embryo came from, whose uterus carried the risk, and what each additional attempt cost in money, months, and biological reserve. For me, after AMH 1.1 and only one euploid embryo, the answer leaned away from repeating retrievals in Thailand and toward protecting the embryo I already had.
My conclusion is not that Thailand IVF is bad or that Malaysia surrogacy is magic. It is that low ovarian reserve punishes vague decisions. Get age-matched lab rates, ask for exact blastocyst and euploidy numbers, read the surrogate obstetric file, and compare time-to-embryo rather than clinic slogans. Anyone considering surrogacy should also confirm current local law, clinic licensing, contracts, parentage rules, and medical suitability with independent professionals before paying anything. When your AMH is 1.1, the brave choice is not chasing one more retrieval; it is choosing the path where a single healthy embryo has the best possible environment and the fewest unnecessary gambles.